MAM
AQST icon

Meeder Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Meeder Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,276
Closed -$6K – 2158
2020
Q2 		$6K Sell
1,276
-2,342
-65% -$10.8K ﹤0.01% 1455
2020
Q1 		$8K Buy
3,618
+650
+22% +$2.47K ﹤0.01% 1601
2019
Q4 		$17K Sell
2,968
-5,161
-63% -$26.9K ﹤0.01% 1400
2019
Q3 		$26K Buy
8,129
+6,678
+460% +$25K ﹤0.01% 1218
2019
Q2 		$6K Sell
1,451
-43
-3% -$220 ﹤0.01% 1597
2019
Q1 		$10K Sell
1,494
-1,799
-55% -$12.6K ﹤0.01% 1234
2018
Q4 		$20K Buy
+3,293
New +$41.6K ﹤0.01% 1065

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's AQST Position: Q3 2020 in Review

Meeder Asset Management sold out of Aquestive Therapeutics (AQST) in Q3 2020, closing a stake of 1,276 shares — an estimated $6K sold.

Meeder Asset Management first reported a position in AQST in Q4 2018 and held it in 7 quarters. The position peaked at $26K in Q3 2019. 60 funds tracked by Wall St. Rank hold AQST as of Q3 2020.

  • Meeder Asset Management reported no remaining Aquestive Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,276 Aquestive Therapeutics shares in Q3 2020, an estimated $6K.
  • Meeder Asset Management first reported a position in Aquestive Therapeutics in Q4 2018 and held it in 7 quarters.
  • Meeder Asset Management's Aquestive Therapeutics position peaked at $26K in Q3 2019.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.